Patents by Inventor Juan Ignacio Luengo
Juan Ignacio Luengo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10975056Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: GrantFiled: June 13, 2017Date of Patent: April 13, 2021Assignees: GlaxoSmithKline Intellectual Property Development Limited, Cancer Research Technology Ltd.Inventors: Nicholas David Adams, Andrew B. Benowitz, María Lourdes Rueda Benede, Karen Anderson Evans, David T Fosbenner, Bryan Wayne King, Mei Li, Juan Ignacio Luengo, William Henry Miller, Alexander Joseph Reif, Stuart Paul Romeril, Stanley J. Schmidt, Roger J. Butlin, Kristin M. Goldberg, Allan M. Jordan, Christopher S. Kershaw, Ali Raoof, Bohdan Waszkowycz
-
Publication number: 20190194166Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: ApplicationFiled: June 13, 2017Publication date: June 27, 2019Inventors: Nicholas David ADAMS, Andrew B. BENOWITZ, María Lourdes Rueda BENEDE, Karen Anderson EVANS, David T. FOSBENNER, Bryan Wayne KING, Mei LI, Juan Ignacio LUENGO, William Henry MILLER, Alexander Joseph REIF, Stuart Paul ROMERIL, Stanley J. SCHMIDT, Roger J. BUTLIN, Kristen M. GOLDBERG, Allan M. JORDAN, Christopher S. KERSHAW, Ali RAOOF, Bohdan WASZKOWYCS
-
Patent number: 9096605Abstract: PI3K? selective compounds having the structureType: GrantFiled: June 29, 2012Date of Patent: August 4, 2015Assignee: GlaxoSmithKline LLCInventors: Hong Lin, Juan Ignacio Luengo, Michael Lee Moore, Junya Qu, Ralph A. Rivero, Rosanna Tedesco, Hongyi Yu
-
Patent number: 8778937Abstract: This invention relates to the use of benzimidazole boronic acid derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazole boronic acids in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazole boronic acid compounds for treating cancer.Type: GrantFiled: November 12, 2012Date of Patent: July 15, 2014Assignee: GlaxoSmithKline LLCInventors: Ralph A. Rivero, Rosanna Tedesco, Juan Ignacio Luengo
-
Patent number: 6545031Abstract: Novel pyrroles, pyrazoles and triazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists as described.Type: GrantFiled: October 30, 2000Date of Patent: April 8, 2003Assignee: SmithKline Beecham CorporationInventors: Juan Ignacio Luengo, John Duncan Elliott, Jia-Ning Xiang
-
Patent number: 6482956Abstract: Novel pyrroles, pyrazoles and triazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.Type: GrantFiled: November 30, 2001Date of Patent: November 19, 2002Assignee: SmithKline Beecham CorporationInventors: Juan Ignacio Luengo, John Duncan Elliott
-
Publication number: 20020072614Abstract: Novel pyrroles, pyrazoles and triazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.Type: ApplicationFiled: November 30, 2001Publication date: June 13, 2002Inventors: Juan Ignacio Luengo, John Duncan Elliott
-
Patent number: 6353116Abstract: Novel pyrroles, pyrazoles and triazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.Type: GrantFiled: December 14, 1999Date of Patent: March 5, 2002Assignee: SmithKline Beecham CorporationInventors: Juan Ignacio Luengo, John Duncan Elliott
-
Patent number: 6174906Abstract: Novel to isooxazoles, oxazoles, thiazoles, isothiazoles and imidazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.Type: GrantFiled: October 1, 1999Date of Patent: January 16, 2001Assignee: SmithKline Beecham CorporationInventors: John Duncan Elliott, Juan Ignacio Luengo, Jia-Ning Xiang
-
Patent number: 6107304Abstract: Invented are substituted thieno (2,3-b)pyrazolo(3,4-d)pyridin-3-ones, pharmaceutical compositions containing these compounds, and methods of using these compounds to enhance erythropoiesis. Also invented are intermediates and processess used in preparing these compounds.Type: GrantFiled: June 7, 1999Date of Patent: August 22, 2000Assignee: SmithKline Beecham CorporationInventor: Juan Ignacio Luengo
-
Patent number: 6096897Abstract: Novel pyrroles, pyrazoles and triazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.Type: GrantFiled: June 29, 1999Date of Patent: August 1, 2000Assignee: SmithKline Beecham CorporationInventors: Juan Ignacio Luengo, John Duncan Elliott
-
Patent number: 6030970Abstract: Novel to isooxazoles, oxazoles, thiazoles, isothiazoles and imidazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.Type: GrantFiled: February 2, 1998Date of Patent: February 29, 2000Assignee: Smithkline Beecham CorporationInventors: John Duncan Elliott, Juan Ignacio Luengo, Jia-Ning Xiang
-
Patent number: 5969151Abstract: This is a continuation of application Ser. No. 08/718,562, filed Sep. 30, 1996, which is a 371 of International Application No. PCT/US96/12581, filed Aug. 2, 1996; which claims the benefit of priority from the following provisional applications: 60/001,792, filed Aug. 2 1995 and 60/010,982, filed Feb. 1, 1996.Type: GrantFiled: July 23, 1998Date of Patent: October 19, 1999Assignee: SmithKline Beecham CorporationInventors: Juan Ignacio Luengo, John Duncan Elliott
-
Patent number: 5958968Abstract: Novel pyrroles, pyrazoles and triazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.Type: GrantFiled: January 8, 1999Date of Patent: September 28, 1999Assignee: SmithKline Beecham CorporationInventors: Juan Ignacio Luengo, John Duncan Elliott
-
Patent number: 5728710Abstract: Rapamycin derivatives; pharmaceutical compositions comprising such rapamycin derivatives and pharmaceutically acceptable carriers or diluents; and methods of using such derivatives to inhibit pathogenic fungi growth inhibition, inhibit immunosuppression or treat carcinogenic tumors are disclosed.Type: GrantFiled: March 16, 1995Date of Patent: March 17, 1998Assignee: SmithKline Beecham CorporationInventor: Juan Ignacio Luengo
-
Patent number: 5661156Abstract: Rapamycin derivatives of formula ##STR1## pharmaceutical compositions comprising such rapamycin derivatives and pharmaceutically acceptable carriers or diluents; and methods of using such derivatives to inhibit pathogenic fungal growth, cause therapeutically desirable immunosuppression, or treat carcinogenic tumors are disclosed.Type: GrantFiled: March 6, 1995Date of Patent: August 26, 1997Assignee: SmithKline Beecham CorporationInventors: Dennis Alan Holt, Juan Ignacio Luengo, Leonard Walter Rozamus, Jr.
-
Patent number: 5648361Abstract: Rapamycin derivatives; pharmaceutical compositions comprising such rapamycin derivatives and pharmaceutically acceptable carriers or diluents; and methods of using such derivatives to inhibit pathogenic fungi growth, inhibit immunosuppression or treat carcinogenic tumors are disclosed.Type: GrantFiled: March 15, 1995Date of Patent: July 15, 1997Assignee: SmithKline Beecham CorporationInventors: Dennis Alan Holt, Juan Ignacio Luengo, Leonard Walter Rozamus, Jr.
-
Patent number: RE37421Abstract: Rapamycin derivatives; pharmaceutical compositions comprising such rapamycin derivatives and pharmaceutically acceptable carriers or diluents; and methods of using such derivatives to inhibit pathogenic fungi growth, inhibit immunosuppression or treat carcinogenic tumors are disclosed.Type: GrantFiled: July 23, 1999Date of Patent: October 23, 2001Assignee: SmithKline Beecham CorporationInventors: Dennis Alan Holt, Juan Ignacio Luengo, Leonard Walter Rozamus, Jr.